Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction.

MLA

Ahn, Sun Tae, et al. “Treatment Persistence with a Fixed-Dose Combination of Tadalafil (5 Mg) and Tamsulosin (0.4 Mg) and Reasons for Early Discontinuation in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction.” Investigative and Clinical Urology, vol. 61, no. 1, Jan. 2020, pp. 81–87. EBSCOhost, https://doi.org/10.4111/icu.2020.61.1.81.

APA

Ahn, S. T., Lee, D. H., Jeong, H. G., Kim, J. W., Oh, M. M., Park, H. S., & Moon, D. G. (2020). Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction. Investigative and Clinical Urology, 61(1), 81–87. https://doi.org/10.4111/icu.2020.61.1.81

Chicago

Ahn, Sun Tae, Dong Hyun Lee, Hyeong Guk Jeong, Jong Wook Kim, Mi Mi Oh, Hong Seok Park, and Du Geon Moon. 2020. “Treatment Persistence with a Fixed-Dose Combination of Tadalafil (5 Mg) and Tamsulosin (0.4 Mg) and Reasons for Early Discontinuation in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction.” Investigative and Clinical Urology 61 (1): 81–87. doi:10.4111/icu.2020.61.1.81.